These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25556809)

  • 21. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB; Kuczenski R; Niculescu AB
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
    Munetz MR; Cornes CL
    J Clin Psychopharmacol; 1983 Dec; 3(6):343-50. PubMed ID: 6139392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological treatment of tardive dyskinesia: recent developments.
    Caroff SN; Campbell EC; Carroll B
    Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levetiracetam in tardive dyskinesia: an open label study.
    Konitsiotis S; Pappa S; Mantas C; Mavreas V
    Mov Disord; 2006 Aug; 21(8):1219-21. PubMed ID: 16637037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covert dyskinesia associated with aripiprazole: a case report and review of the literature.
    Moseley CN; Simpson-Khanna HA; Catalano G; Catalano MC
    Clin Neuropharmacol; 2013; 36(4):128-30. PubMed ID: 23860346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool.
    Bhidayasiri R; Kane JM; Frei KP; Caroff SN; Correll CU; Fahn S; Jankovic J; Hauser RA; Truong DD
    Parkinsonism Relat Disord; 2020 Aug; 77():141-145. PubMed ID: 32823151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tardive dyskinesia.
    Clyne KE; Juhl R
    Am J Hosp Pharm; 1976 May; 33(5):481-6. PubMed ID: 1274963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia.
    Seeman P; Tinazzi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():178-83. PubMed ID: 23454261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
    Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
    Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and emerging treatments for symptomatic tardive dyskinesia.
    Rana AQ; Chaudry ZM; Blanchet PJ
    Drug Des Devel Ther; 2013; 7():1329-40. PubMed ID: 24235816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Propranolol therapy for tardive dyskinesia revisited.
    Factor SA
    Mov Disord; 2012 Nov; 27(13):1703. PubMed ID: 23192928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.